Production (Stage)
AstraZeneca PLC
AZN
$70.41
$0.460.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.48% | 18.03% | 13.81% | 10.45% | 8.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.48% | 18.03% | 13.81% | 10.45% | 8.60% |
| Cost of Revenue | 15.80% | 20.12% | 75.45% | 43.26% | 19.11% |
| Gross Profit | 15.41% | 17.59% | 5.95% | 5.36% | 6.60% |
| SG&A Expenses | 5.59% | 8.46% | -0.44% | 3.57% | 5.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 75.88% | 81.25% | 78.34% | 74.84% | -148.37% |
| Total Operating Expenses | 13.18% | 16.44% | 19.13% | 16.21% | 8.65% |
| Operating Income | 23.27% | 23.52% | 0.20% | -5.25% | 8.44% |
| Income Before Tax | 24.96% | 25.97% | 16.84% | 28.03% | 76.69% |
| Income Tax Expenses | 37.36% | 75.91% | 62.33% | 1,202.54% | 320.44% |
| Earnings from Continuing Operations | 22.80% | 18.12% | 10.09% | 4.49% | 34.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -66.67% | 0.00% | 37.50% | 16.67% | -50.00% |
| Net Income | 22.76% | 18.14% | 10.16% | 4.51% | 34.59% |
| EBIT | 23.27% | 23.52% | 0.20% | -5.25% | 8.44% |
| EBITDA | 16.78% | 16.70% | 0.48% | -4.50% | 3.33% |
| EPS Basic | 22.70% | 18.10% | 10.14% | 4.49% | 34.53% |
| Normalized Basic EPS | 26.96% | 26.71% | 0.27% | -5.87% | 8.45% |
| EPS Diluted | 22.60% | 18.00% | 9.87% | 4.40% | 34.57% |
| Normalized Diluted EPS | 26.94% | 26.70% | 0.21% | -5.92% | 8.41% |
| Average Basic Shares Outstanding | 0.05% | 0.03% | 0.02% | 0.02% | 0.03% |
| Average Diluted Shares Outstanding | 0.06% | 0.05% | 0.06% | 0.05% | 0.05% |
| Dividend Per Share | 6.90% | 6.90% | 2.41% | 2.41% | 0.00% |
| Payout Ratio | -0.10% | -0.13% | -0.06% | -0.04% | -0.25% |